Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

NCT ID: NCT00783185

Last Updated: 2010-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychotic Disorders Marijuana Abuse Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACT

Anti-Cannabis-Consumption-Training

Group Type EXPERIMENTAL

Cannabis-Consumption-Reduction-Training

Intervention Type BEHAVIORAL

8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse

CG

Control group

Group Type ACTIVE_COMPARATOR

Social competence Training

Intervention Type BEHAVIORAL

8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis-Consumption-Reduction-Training

8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse

Intervention Type BEHAVIORAL

Social competence Training

8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of schizophrenia and disorders with psychotic features
* Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria

* Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)
* Discharge from hospital before completion of training
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Konstanz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Konstanz

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hans Watzl, Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Konstanz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Konstanz

Konstanz, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRET

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Enhancing Recovery in Early Schizophrenia
NCT02926859 ACTIVE_NOT_RECRUITING PHASE2